Nanomedicine (Lond). 2014 Apr;9(4):407-20. doi: 10.2217/NNM.13.21.
In the present study, the anticancer efficacy of a novel escheriosome-based formulation of PLK1-specific siRNA was evaluated against liver cancer in BALB/c mice.
MATERIALS & METHODS: The escheriosome-based siRNA nanoparticles were prepared using lipids isolated from Escherichia coli. The escheriosomes were characterized for size, surface charge and stability. The anticancer potential of PLK1-specific siRNA formulation was ascertained on the basis of expression of pro-/anti-apoptotic factors and histopathological studies.
The escheriosome-entrapped siRNA was found to be released in surrounding milieu in a sustained manner. The nanoformulation was successful in modulating proapoptotic factors and eventually helped in better survival of the treated animals.
Our data demonstrate the efficacy of systemically administered siRNA in the treatment of experimental liver cancer. This novel therapeutic strategy may be applicable to a broad range of cancers in patients with the obstinate form of the disease.
本研究评估了新型质体蓝素囊泡载药系统中 PLK1 特异性 siRNA 对 BALB/c 小鼠肝癌的抗癌疗效。
采用从大肠杆菌中分离的脂质制备质体蓝素囊泡载药系统 siRNA 纳米粒。对质体蓝素囊泡进行粒径、表面电荷和稳定性分析。基于促凋亡/抗凋亡因子的表达和组织病理学研究，确定 PLK1 特异性 siRNA 制剂的抗癌潜力。
发现质体蓝素囊泡包载的 siRNA 能持续释放到周围环境中。纳米制剂成功调节了促凋亡因子，最终有助于提高治疗动物的生存率。
我们的数据证明了系统给药的 siRNA 在治疗实验性肝癌中的疗效。这种新的治疗策略可能适用于患有顽固型疾病的患者的广泛癌症。
